Navigation Links
Leukemic cells find safe haven in bone marrow

The cancer drug asparaginase fails to help cure some children with acute lymphoblastic leukemia (ALL) because molecules released by certain cells in the bone marrow counteract the effect of that drug, according to investigators at St. Jude Children's Research Hospital.

The researchers showed that mesenchymal cells in the bone marrow create a protective niche for leukemic cells by releasing large amounts of asparagine, an amino acid that nearby leukemic cells must have to survive but do not make efficiently. This extra supply of asparagine helps leukemic cells survive treatment with asparaginase, a drug that normally would deplete their supply of this vital nutrient, the researchers reported. Mesenchymal cells give rise to a variety of different tissues, such as osteoblasts (bone-building cells) and chondrocytes (cartilage-building cells), and form the nurturing environment where normal blood cells and leukemic cells grow.

"Leukemic cells that resist asparaginase and survive in this protective niche of the bone marrow might be the reason that leukemia recurs in some children who have been treated with this drug," said Dario Campana, M.D., Ph.D., a member of the St. Jude Oncology and Pathology departments.

Campana is senior author of the report that appears in the online pre-publication issue of "The Journal of Clinical Investigation."

"Our findings indicate that the level of activity of the "ASNS" gene in the mesenchymal cells is key to protecting leukemic cells in the bone marrow from asparaginase," Campana said. "This insight will help researchers find ways to disrupt this safe haven for leukemic cells that need asparagine," added James R. Downing, M.D., St. Jude scientific director and chair of the Pathology department. Downing is a co-author of "The Journal of Clinical Investigation" paper. The "ASNS" gene controls production of the enzyme asparagine synthetase (ASNS), which leukemic cells use to make asparagine.

< p>The study’s findings also suggest that drugs now being developed to block ASNS should be tested to see if they also prevent mesenchymal cells from making this amino acid. In addition, the ability of mesenchymal cells to make asparagine might be decreased by cancer drugs that are already known to disrupt the activity of those cells.

"Because asparaginase is so widely used to treat ALL, this new insight into how mesenchymal cells protect leukemic cells is very important," said Ching-Hon Pui, M.D., chair of the Oncology department and American Cancer Society Professor at St. Jude. "The more we learn about the molecular interactions between these cells, the more likely we’ll be able to enhance the anti-leukemic action of asparaginase and perhaps other anti-leukemic drugs as well," said Pui, a co-author of the paper. "That would reduce the recurrence rate of ALL and continue our successful efforts to increase the survival rate of ALL."

Previous research at St. Jude and elsewhere had shown that direct contact with bone marrow mesenchymal cells is essential for the long-term survival and multiplication of leukemic lymphoblasts. In the current study, the team found that the gene for ASNS was more than 20 times active in producing this enzyme in mesenchymal cells than in ALL cells.

Experiments performed by co-authors Shotaro Iwamoto, M.D., and Keichiro Mihara, postdoctoral fellows in Campana’s laboratory, demonstrated that ALL cells from different patients became much more resistant to asparaginase when cultured on top of a layer of mesenchymal cells. In order to determine whether it was the high levels of asparagine released by mesenchymal cells that protected ALL cells from asparaginase, the St. Jude team repeated the experiment, but blocked the ability of mesenchymal cells to make the ASNS enzyme and produce asparagine. In this case, the protective effect of mesenchymal cells was eliminated. Conversely, when the researchers caused the AS NS gene to work overtime making asparagine, the ability of the mesenchymal cells layer to protect the ALL cells was significantly enhanced. The team also showed that the more actively "ASNS" genes produced ASNS in mesenchymal cells, the higher levels of asparagine they released.
'"/>

Source:St. Jude Children's Research Hospital


Related biology news :

1. Wisconsin scientists grow critical nerve cells
2. Spleen may be source of versatile stem cells
3. Researchers discover way to make cells in the eye sensitive to light
4. Priming embryonic stem cells to fulfill their promise
5. Lack of enzyme turns fat cells into fat burners
6. Poor prenatal nutrition permanently damages function of insulin-producing cells in the pancreas
7. Elusive HIV shape change revealed; Key clue to how virus infects cells
8. Mouse brain cells rapidly recover after Alzheimers plaques are cleared
9. Enzyme allows B cells to resist death, leading to leukemia
10. Scientists rid stem cell culture of key animal cells
11. Genetically modified natural killer immune cells attack, kill leukemia cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
(Date:4/19/2017)... , April 19, 2017 The ... vendor landscape is marked by the presence of several ... however held by five major players - 3M Cogent, ... companies accounted for nearly 61% of the global military ... companies in the global military biometrics market boast global ...
(Date:4/13/2017)... 2017 UBM,s Advanced Design and Manufacturing event ... emerging and evolving technology through its 3D Printing and ... alongside the expo portion of the event and feature ... focused on trending topics within 3D printing and smart ... event will take place June 13-15, 2017 at the Jacob ...
Breaking Biology News(10 mins):
(Date:7/20/2017)... , ... July 20, 2017 , ... VIC Technology ... joining the company’s board of directors. This addition continues to strengthen and diversify ... Calvin Goforth, CEO and Chairman. “He is a highly accomplished business executive with a ...
(Date:7/20/2017)... ... July 20, 2017 , ... Corporate Directors Forum is ... 27th annual Director of the Year Awards. , The awards will be presented Thursday, ... This annual event celebrates directors who have made significantly positive contributions in the boardrooms ...
(Date:7/18/2017)... , ... July 18, 2017 , ... Sourcing custom glass ... your needs and has the capabilities to properly execute your job can take many ... is a sourcing portal designed to showcase the company’s capabilities and core ...
(Date:7/18/2017)... San Antonio, Texas (PRWEB) , ... July 18, 2017 , ... ... that can affect patients across the region. Nationally, summer is a struggle for community ... This is why the San Antonio Chamber of Commerce is teaming up ...
Breaking Biology Technology: